Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5MS-5
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
01
Overview
5MS-5: sourced facts only. name: "Subsequent catalog-based structure-activity relationship (SAR) optimization led to the identification of validated hits, 5MS-5 and 19MS-5, which exhibit direct CD28 binding and potent inhibition of CD28-B7 interactions in cellular reporter assays." [PMID:41269130]; target: "Subsequent catalog-based structure-activity relationship (SAR) optimization led to the identification of validated hits, 5MS-5 and 19MS-5, which exhibit direct CD28 binding and potent inhibition of CD28-B7 interactions in cellular reporter assays." [PMID:41269130]; developer: "Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, New York 10065, United States." [PMID:41269130]
02
Targets
CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on 5MS-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5MS-5.